VolitionRx (VNRX) Shoots Up 23% As Company Signs Global Supply Agreement For Nu.Q Vet Cancer Test
VolitionRx (VNRX) shot up 23% after announcing that VNRX signed Global Supply Agreement for Nu.Q Vet Cancer Test.
Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC commented: “The Nu.Q® Vet Cancer Test was developed with the goal of providing an accessible and affordable screening test to aid early detection. This supply agreement is an exciting moment for Volition as we continue to commercialize our Nu.Q® technology within the companion animal healthcare sector and capitalize on what we believe to be significant mass market opportunities. We share the Company’s mission of advancing pet healthcare and are delighted to be working with them. Additional information will be shared in the coming months, including estimated dates of test availability.”
About Volition
Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.
The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. Such website addresses are included in this document as an inactive textual references only.
